|
October 9, 2025
Strong Results for Lenacapavir PrEP Study Among Adolescents
By Ethan Covey
Lenacapavir (LEN; Yeztugo, Gilead) twice yearly given as pre-exposure prophylaxis (PrEP) is safe and efficacious in adolescents and young adults, according to data from the PURPOSE-1 trial.
The findings address a key population that often is not included in clinical trials, investigators said. “Adolescents are often excluded from clinical trials due to stringent ethical and regulatory guidelines intended to protect them,” said Katherine Gill, MBChB, MPH, a senior researcher at the Desmond Tutu Health Foundation, in Cape Town, South Africa.
Engaging With Adolescents
However, the PURPOSE program, which is supported by Gilead Sciences, was organized intentionally to include adolescents 16 and 17 years old.
“[This marks] a significant step toward equitable HIV prevention research, and is important as adolescents continue to account for a significant proportion of global HIV infections, yet there are often prolonged delays between the availability of adult data and adolescent-specific data,” Dr. Gill said. “Additionally, many adolescents face challenges with adhering to daily oral medications due to factors such as stigma, pill fatigue and complex daily routines.”
Continue reading... https://www.idse.net/Pediatric-Infections/Article/10-25/Long-Acting-PrEP-lenacapavir-HIV-Adolescents-teens-Efficacy/78482
CONTACT
Marie Rosenthal
MRosenthal@McMahonmed.com
"Reproduced with permission - Infectious Disease Special Edition (IDSE)"
Infectious Disease Special Edition (IDSE)
Back to ...
Positively Positive - Living with HIV/AIDS:
HIV/AIDS News
For more HIV and AIDS News visit...
Positively Positive - Living with HIV/AIDS: HIV/AIDS News Archive
|
